This study focuses on individuals who have advanced colorectal cancer that has spread up to 4 body sites. The purpose of the study is to compare the usual treatment alone to ablative local therapy (ALT) to all known metastatic tumor sites plus the usual treatment. The usual treatment is treatment with intravenous and/or oral medications (systemic therapy). These medications help stop the cancer sites from getting larger and prevent the spread of the cancer to additional body sites. ALT is commonly used to treat all known tumor sites and may be performed by surgery, radiation therapy, heat with microwave ablation, or other methods. This study will use radiation therapy and potentially surgery and/or heat. To measure the effectiveness of the addition of ALT to treatment, researchers will examine whether this approach increases the life of patients by 17 months or more compared to the usual approach. Participants will be assigned to one of two groups. Group 1 will receive the usual drug therapy used to treat metastatic colorectal cancer plus ALT to all known metastatic sites. Group 2 will receive the usual systemic drug therapy used to treat metastatic colorectal cancer and may also receive palliative local therapies to metastatic sites such as surgery or radiation to help relieve uncontrolled symptoms, such as pain, caused by cancer.
What is the full name of this clinical trial?
A022101: A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery